This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

STEPHEN L. COCHI, MD; STEPHEN R. PREBLUD, MD; WALTER A. ORENSTEIN, MD
Surveillance, Investigations, and Research Branch Division of Immunization Center for Prevention Services Centers for Disease Control Atlanta, GA 30333

Am J Dis Child. 1988;142(10):1021-1022.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Dr Bader raises an important issue that was the subject of some controversy for several years^1,2 following the introduction of live attenuated virus mumps vaccine in the United States in December 1967. In retrospect, routine use of the mumps vaccine as soon as it was introduced might have prevented the circumstances that have led to the relative resurgence in mumps recently observed. Most expert opinions at the time of vaccine licensure, and for approximately ten years thereafter, did not recommend priority be given to mumps vaccination. Low priority for mumps vaccination was the result of a variety of factors, including doubts about the duration of immunity conferred by mumps vaccine in the absence of long-term efficacy data and a lack of epidemiologic data on the health impact of mumps that were as convincing as, for example, those for poliomyelitis, rubella, and measles.² In the absence of strong recommendations, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?